Table 2.

The effects of gliotoxin and C1-3-gliotoxin on parameters of liver fibrosis in a sustained carbon tetrachloride model of liver fibrosis [21]

Treatment	Number of myofibroblasts	Number of F4/80 cells	Fibrosis severity	MMP-13 levels
DMSO vehicle	+++++	+++	++++	++++
Free gliotoxin	+++a	++a	++++	+++a
PBS	+++++	+++	++++	++++
C1-3
C1-3-gliotoxin	+b	+++	++b	++++
CSBD9	+++++	+++	++++	++++
CSBD9-gliotoxin	+++++	+++	++++	++++

Mice were administered CCl₄ over a 8-week period as outlined [21] and the liver was examined for myofibroblasts via α-smooth muscle actin immunostaining [11]; Kupffer cells by immunostaining for F4/80 [21]; fibrosis severity through histochemical staining with Sirius red [11]; and MMP-13 levels by immunohistochemistry [21]. Note, gliotoxin was administered in DMSO at a dose of 0.6 mg/kg body weight. ScAbs were administered in phosphate-buffered saline (PBS) at a dose of 20 mg of protein/kg body weight. Mice received conjugates at an equivalent dose of 0.6 mg of gliotoxin/kg body weight. Data are blinded examination of staining intensity in liver sections from five animals per treatment group—significantly different (two tailed) from ^aDMSO control or ^bPBS control using Student’s T test (P > 95%) [21]